Immunotherapies for COVID-19: lessons learned from sepsis.

Remy, Kenneth E;Brakenridge, Scott C;Francois, Bruno;Daix, Thomas;Moldawer, Lyle L;et.al.
(2020) The Lancet Respiratory Medicine — Vol. 8, n° 10, p. 946-949 (2020)

Files

2020_Remy_Lancet_Respir_Med.pdf
  • Open Access
  • Adobe PDF
  • 200.51 KB

Details

Authors
  • Remy, Kenneth E
    Author
  • Brakenridge, Scott C
    Author
  • Francois, Bruno
    Author
  • Daix, Thomas
    Author
  • Laterre, Pierre-FrançoisUCLouvain
    Author
  • Moldawer, Lyle L
    Author
Show more
Abstract
Therapeutic approaches to mitigate the severe acute lung injury associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have rapidly entered clinical trials primarily on anecdotal observations and few clinical studies. Along with the clinical symptoms related to viral invasion, the reported molecular response known as the cytokine storm has attracted the greatest attention, in both the scientific and the lay press, as a cause of organ injury. [...]
Affiliations

Citations

Remy, K. E., Brakenridge, S. C., Francois, B., Daix, T., Deutschman, C. S., Monneret, G., Jeannet, R., Laterre, P.-F., Hotchkiss, R. S., & Moldawer, L. L. (2020). Immunotherapies for COVID-19: lessons learned from sepsis. The Lancet Respiratory Medicine, 8(10), 946-949. https://doi.org/10.1016/S2213-2600(20)30217-4 (Original work published 2020)